| Usable length 80 cm | Usable length 130 cm | Balloon diameter (mm) | Balloon length (mm) | Recommended introducer sheath (Fr) | Nominal pressure (atm) | RBP (atm) |
|---|---|---|---|---|---|---|
| IAV04004008P | — | 4 | 40 | 5 | 8 | 14 |
| IAV04006008P | — | 4 | 60 | 5 | 8 | 14 |
| IAV04008008P | — | 4 | 80 | 5 | 8 | 14 |
| IAV04012008P | — | 4 | 120 | 5 | 8 | 14 |
| IAV05004008P | — | 5 | 40 | 6 | 8 | 14 |
| IAV05006008P | — | 5 | 60 | 6 | 8 | 14 |
| IAV05008008P | — | 5 | 80 | 6 | 8 | 14 |
| IAV05012008P | — | 5 | 120 | 6 | 8 | 14 |
| IAV06004008P | — | 6 | 40 | 6 | 8 | 14 |
| IAV06006008P | — | 6 | 60 | 6 | 8 | 14 |
| IAV06008008P | — | 6 | 80 | 6 | 8 | 14 |
| IAV06012008P | — | 6 | 120 | 6 | 8 | 14 |
| IAV07004008P | — | 7 | 40 | 7 | 8 | 14 |
| IAV07006008P | — | 7 | 60 | 7 | 8 | 14 |
| IAV07008008P | — | 7 | 80 | 7 | 8 | 14 |
| IAV08004008P | IAV08004013P | 8 | 40 | 7 | 8 | 10 |
| IAV08006008P | IAV08006013P | 8 | 60 | 7 | 8 | 10 |
| IAV08008008P | IAV08008013P | 8 | 80 | 7 | 8 | 10 |
| IAV09004008P | IAV09004013P | 9 | 40 | 7 | 8 | 10 |
| IAV09006008P | IAV09006013P | 9 | 60 | 7 | 8 | 10 |
| IAV09008008P | IAV09008013P | 9 | 80 | 7 | 8 | 10 |
| IAV10004008P | IAV10004013P | 10 | 40 | 7 | 6 | 9 |
| IAV12004008P | IAV12004013P | 12 | 40 | 9 | 6 | 9 |
Peripheral drug-coated balloons
IN.PACT™ AV drug-coated balloon
<p>The IN.PACT™ AV drug-coated balloon (DCB) is used for arteriovenous (AV) access maintenance.</p>
Features
The IN.PACT™ AV DCB is a clinically demonstrated endovascular therapy for end-stage renal disease (ESRD) patients with a narrowed AV fistula. It delivers an antiproliferative drug (paclitaxel) to the vessel to inhibit neointimal hyperplasia (NIH), the primary cause of AV fistula stenosis. The proprietary design enables the IN.PACT™ AV DCB to deliver sustained drug levels and unparalleled clinical results.1
Specifications
| Product characteristic | Description |
|---|---|
| Balloon coating | Paclitaxel and urea |
| Catheter shaft design | Over-the-wire (OTW) |
| Sterilization method | Ethylene oxide (ETO) |
| Shaft diameter | 5 Fr |
| Catheter effective length | 80, and 130 cm |
| Balloon lengths | 40 to 120 mm |
| Nominal balloon pressure | 4.0–9.0 mm — 8 atm; 10.0–12.0 mm — 6 atm |
| Rated burst pressure | 4.0–7.0 mm — 14 atm; 8.0–9.0 mm — 10 atm; 10.0 mm — 9 atm; 12.0 mm — 9 atm |
| Balloon diameters | 4.0 to 12.0 mm |
| Introducer sheath compatibility | 4.0 mm — 5 Fr; 5.0–6.0 mm — 6 Fr; 7.0–10 mm — 7 Fr; 12.0 mm — 9 Fr |
| Balloon fold configuration | 4.0 mm 3 folds; 5 — 12 mm 6 folds |
| Paclitaxel drug dose | 3.5 μg/mm2 |
| Guidewire compatibility | 0.035" |
Ordering information
Related links
† Target lesion primary patency in an AV fistula IDE randomized controlled trial.
‡ The largest global, randomized, AV fistula drug-coated balloon study conducted, with subjects from Japan, New Zealand, and the United States.
- Lookstein RA, Haruguchi H, Ouriel K, et al. IN.PACT™ AV access investigators. Drug-coated balloons for dysfunctional dialysis arteriovenous fistulas. N Engl J Med. 2020;383(8):733-742. Highlighted results reported at both 180 and 210 days.
- Data on file at Medtronic.
This product is licenced with Health Canada as "IN.PACT AV PACLITAXEL-COATED PTA BALLOON CATHETER" on Health Canada licence number "MDL#104501".